… German claims data to compare the effectiveness and safety of newly-initiated apixaban and
VKA therapy in NVAF patients… stroke risk with apixaban in routine practice compared to VKA …

… , dabigatran vs apixaban, and rivaroxaban vs apixaban were performed following … relative
effectiveness and safety of dabigatran vs VKA among the PS-trimmed and PS-matched patient …

… vitamin K antagonist (VKA). There is little evidence documenting … A retrospective cohort study
using a German claims … predominant VKA in clinical practice, comparative data for NOACs …

… OR new oral anticoagulants OR novel oral anticoagulants OR dabigatran OR rivaroxaban
OR apixaban OR edoxaban AND vitamin-K antagonists OR warfarin OR coumadin OR …

… , Antwerp, Belgium; 6Faculty of Medicine and Life Sciences, Hasselt University, Hasselt,
Belgium; 7Department of Neurology, Universitätsklinikum Würzburg, Würzburg, Germany; …

… (rivaroxaban, apixaban, and edoxaban), have been shown to be at least as efficacious and
… impact clinical practice and choice of anticoagulants in atrial fibrillation patients. Moreover, …

… choice, particularly in patients newly started on anticoagulation. Both physicians and
patients are becoming more accustomed to the use of these drugs in clinical practice. However, …

… The lack of evidence in such settings is reflected in the wide diversity in clinical practice …
(dabigatran, rivaroxaban, apixaban or edoxaban), patients received aspirin therapy at any time …

… for apixaban (only 18 studies comparing apixaban with VKAs … for apixaban in comparison to
rivaroxaban and dabigatran. … use of NOACs in routine daily practice, confirming RCT findings…

… study was to describe NVAF patients treated with apixaban compared with conventional
VKA in terms of bleeding, stroke and systemic embolic events in daily clinical practice in Spain. …